We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+23.43%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$16.4B
AUM Growth
-$5.58B
(-25%)
Cap. Flow
-$3.87B
Cap. Flow
% of AUM
-23.65%
Top 10 Holdings %
Top 10 Hldgs %
18.07%
Holding
3,458
New
283
Increased
974
Reduced
1,077
Closed
907
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$97.1M |
| 2 |
iShares Core S&P Small-Cap ETF
IJR
|
+$76.6M |
| 3 |
Lowe's Companies
LOW
|
+$75.4M |
| 4 |
Monster Beverage
MNST
|
+$64.6M |
| 5 |
FISV
Fiserv Inc
FISV
|
+$63.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Accenture
ACN
|
+$114M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$109M |
| 3 |
Trane Technologies
TT
|
+$106M |
| 4 |
Microsoft
MSFT
|
+$104M |
| 5 |
Mastercard
MA
|
+$104M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.03% |
| 2 | Healthcare | 13.89% |
| 3 | Financials | 11.27% |
| 4 | Consumer Discretionary | 8.92% |
| 5 | Industrials | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Mastercard
MA
$477B
| $120M | 0.73% |
404,231
-370,208
| -48% | -$104M |
|
27
Biogen
BIIB
$29.9B
| $119M | 0.73% |
446,283
-87,239
| -16% | -$26.2M |
|
28
JPMorgan Chase
JPM
$939B
| $114M | 0.7% |
1,214,234
-346,029
| -22% | -$32.8M |
|
29
Abbott
ABT
$180B
| $114M | 0.69% |
1,242,972
+22,566
| +2% | +$2.04M |
|
30
Colgate-Palmolive
CL
$72.6B
| $111M | 0.68% |
1,515,657
+381,833
| +34% | +$27.1M |
|
31
Merck
MRK
$324B
| $110M | 0.67% |
1,485,565
-471,268
| -24% | -$35.5M |
|
32
Dollar General
DG
$25.9B
| $109M | 0.67% |
573,970
+143,303
| +33% | +$25.9M |
|
33
Chevron
CVX
$388B
| $108M | 0.66% |
1,215,965
+68,174
| +6% | +$6.1M |
|
34
Lam Research
LRCX
$382B
| $106M | 0.65% |
3,281,040
-1,287,730
| -28% | -$35.1M |
|
35
Keysight
KEYS
$54.5B
| $106M | 0.65% |
1,052,697
-99,937
| -9% | -$9.81M |
|
36
AbbVie
ABBV
$458B
| $103M | 0.63% |
1,047,890
+483,003
| +86% | +$42.5M |
|
37
Alphabet (Google) Class C
GOOG
$3.9T
| $101M | 0.62% |
1,431,720
+56,860
| +4% | +$3.84M |
|
38
Cadence Design Systems
CDNS
$90B
| $101M | 0.62% |
1,054,218
-441,184
| -30% | -$36.9M |
|
|
39
Lowe's Companies
LOW
$116B
| $99.6M | 0.61% |
737,084
+660,001
| +856% | +$75.4M |
|
40
RTX Corp
RTX
$287B
| $98.2M | 0.6% |
1,594,207
+554,775
| +53% | +$34.6M |
|
|
41
Bristol-Myers Squibb
BMY
$127B
| $97.7M | 0.6% |
1,661,787
-1,825,581
| -52% | -$109M |
|
42
Vanguard Real Estate ETF
VNQ
$39.9B
| $97.6M | 0.6% |
1,243,355
+278,885
| +29% | +$21.1M |
|
43
Honeywell
HON
$77.1B
| $96.9M | 0.59% |
710,719
-333,090
| -32% | -$44.1M |
|
44
Pfizer
PFE
$140B
| $94.4M | 0.58% |
3,041,904
-512,746
| -14% | -$17.4M |
|
45
Intercontinental Exchange
ICE
$82.4B
| $93.6M | 0.57% |
1,021,549
-23,528
| -2% | -$2.15M |
|
46
Comcast
CMCSA
$79.1B
| $92.3M | 0.56% |
2,366,969
-2,228,624
| -48% | -$84.9M |
|
47
CDW
CDW
$17.1B
| $88.4M | 0.54% |
760,768
-58,548
| -7% | -$6.34M |
|
48
American Tower
AMT
$77.7B
| $87.5M | 0.53% |
338,366
-188,345
| -36% | -$46.6M |
|
49
McKesson
MCK
$98.5B
| $86.6M | 0.53% |
564,398
-157,360
| -22% | -$22.7M |
|
50
Omnicom Group
OMC
$22.7B
| $83.1M | 0.51% |
1,522,851
-949,706
| -38% | -$51.7M |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q2 2020 Portfolio in Review
As of Q2 2020, Glenmede Trust held 3,458 positions worth $16.4B, down 25% from $21.9B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Glenmede Trust withdrew a net $3.87B in Q2 2020, closing 907 positions and reducing 1,077 holdings. Its most notable exit was Raytheon Company, an estimated $66.5M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 19% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Glenmede Trust opened a new position in Carrier Global worth $21.3M.
- Glenmede Trust's largest Q2 2020 buy was Carrier Global: 960,042 shares worth $21.3M.
- Glenmede Trust added most to State Street SPDR S&P 500 ETF Trust in Q2 2020, an estimated $97.1M increase.
- Glenmede Trust's biggest Q2 2020 reduction was Accenture, cutting an estimated $114M.
- Glenmede Trust fully exited Raytheon Company in Q2 2020, selling an estimated $66.5M.
- Glenmede Trust's ten largest holdings make up 18% of its $16.4B portfolio in Q2 2020.
- Glenmede Trust opened 283 new positions and closed 907 in Q2 2020.
- Glenmede Trust's portfolio value fell 25% quarter-over-quarter to $16.4B.
Based on Glenmede Trust's 13F filing for Q2 2020, filed 14 Aug 2020.